As of the latest Form 4 filed Jun 29, 2026.
What Artiva Biotherapeutics, Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 18 most recent filings for ARTV.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-29 | 2026-06-26 | RA CAPITAL MANAGEMENT, L.P. Director | PPurchase | +1.88K | $8.98 | $16.8K | No | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | RA CAPITAL MANAGEMENT, L.P., Director | PPurchase | +31.0K | $8.88 | $275K | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. Director | PPurchase | +125K | $8.89 | $1.11M | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-15 | RA CAPITAL MANAGEMENT, L.P., Director | PPurchase | +15.4K | $8.99 | $139K | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | RA CAPITAL MANAGEMENT, L.P., Director | PPurchase | +391K | $8.57 | $3.35M | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. Director | PPurchase | +549K | $7.91 | $4.34M | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-10 | RA CAPITAL MANAGEMENT, L.P., Director | PPurchase | +103.00 | $7.00 | $721.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | RA CAPITAL MANAGEMENT, L.P., Director | PPurchase | +479K | $6.91 | $3.31M | No | Form 4 ↗ |
| 2026-05-28 | 2026-05-11 | GC Corp. 10% owner | PPurchase | +347K | $11.52 | $4.00M | No | Form 4 ↗ |
| 2026-05-28 | 2026-05-11 | GC Corp., 10% owner | PPurchase | +1.09M | $11.52 | $12.5M | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-19 | Raymon Heather SVP, Research and Development | SSale | −3.10K | $9.01 | $27.9K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-19 | Horan Christopher Chief Tech Operations Officer | SSale | −7.00K | $9.01 | $63.1K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-19 | Bush Jennifer COO, CLO, Compliance Officer | SSale | −8.79K | $9.01 | $79.2K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-19 | Banerjee Subhashis Chief Medical Officer | SSale | −7.04K | $9.01 | $63.4K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-19 | Aslan Fred Chief Executive Officer | SSale | −27.1K | $9.01 | $244K | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-18 | Miralles Gines Diego President & Head of R&D | AAward | +77.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | RA CAPITAL MANAGEMENT, L.P. Director | PPurchase | +6.51M | $11.52 | $75.0M | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-10 | Huston Thad Allen Chief Financial Officer | AAward | +220K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ARTV’s full analysis or the market-wide insider trading feed. The tabs above jump to ARTV’s other SEC data.
Source: SEC Form 4 filings for ARTV, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.